News & Updates

The National Lung Screening Trial (NLST) in Singapore falls short of identifying some individuals, particularly women, who are at an increased risk of developing lung cancer, according to a study. However, those who meet the criteria may derive significant benefits from the screening.

Palbociclib combined with endocrine therapy (ET) is effective in hormone receptor (HR)–positive, HER2-negative advanced breast cancer (ABC) in both first-line (1L) and second-line (2L) settings in the real world, a multicentre observational study in Japan has shown.

Treatment with patritumab deruxtecan (HER3-DXd) confers survival benefits on patients with epidermal growth factor receptor (EGFR)-mutated nonsmall-cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, results of a phase I study have shown.

Neoadjuvant pembrolizumab plus chemotherapy improves event-free survival (EFS) in high-risk, early-stage triple-negative breast cancer (TNBC) patients with residual cancer burden (RCB), suggests a study.

Adults who have tested negative for colorectal cancer (CRC) on initial colonoscopy and have no family history of CRC may only need to undergo a repeat screening after 15 years, according to a new Swedish study.